Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial
B. Pradhan, Irving W. Wainer, Ruin Moaddel, M. Torjman, Michael S. Goldberg, M. Sabia, Tapan Parikh, A. Pumariega
July 1, 2017 DOI: 10.4103/2542-3932.211589 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized, placebo-controlled, cross-over clinical study |
|---|---|
| Sample size | 10 |
| Population | Patients with chronic and refractory post-traumatic stress disorder (PTSD) |
| Interventions | (R S)-ketamine TIMBER psychotherapy |
| Dose | 0.5 mg/kg |
| Duration | 12 TIMBER sessions (3 in first week, then 9 weekly); 18-month follow-up |
| Measures | PTSD Checklist (PCL), Clinician Administered PTSD Scale for DSM-IV (CAPS), 17-item Hamilton Rating Scale for Depression (Ham-D-17), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MoCA), Assessment Scale for Mindfulness Interventions |
| Topics | Depression Esketamine Ketamine Meditation PTSD |
| Registration | NCT02766192 |
| Key points | Nine of ten patients with chronic, refractory PTSD showed robust improvement on PTSD, depression, and anxiety measures after 12 TIMBER sessions combined with either ketamine or placebo, with responses lasting about 32 days on average. Ketamine plus TIMBER produced a numerically longer response than placebo plus TIMBER (33 vs. 25 days), but this difference was not statistically significant. After switching from placebo to ketamine, patients' responses were significantly prolonged (49 vs. 25 days). The authors conclude that TIMBER augmented with low-dose (R,S)-ketamine may prolong ketamine's therapeutic effects and could be a valuable treatment option for PTSD. |
Abstract
Background and
Objectives: Trauma memories lay at the core in etiopathogenesis of post-traumatic stress disorder (PTSD). Using pharmacological and cognitive behavioral treatments that specifically target trauma memories can improve the outcome. Ketamine has been shown to rapidly improve symptoms in PTSD and comorbid depression, but unfortunately these effects are short-lived. Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy is a type of mindfulness based cognitive behavioral therapy that targets the trauma memories. TIMBER psychotherapy in combination with (R,S)-ketamine are increasingly used to treat PTSD and comorbid depression. This study aims to determine if the combination of (R,S)-ketamine chemotherapy and TIMBER psychotherapy would produce a positive synergistic response in patients with PTSD.
Design: This is a randomized, placebo-controlled, cross-over clinical study.
Methods: Because response to ketamine alone is short-lived, this study combined TIMBER with a single infusion of 0.5 mg/kg (R,S)-ketamine to sustain its therapeutic effects. Ten patients with chronic and refractory PTSD were randomly assigned to two groups (n = 5 each): TIMBER-K group patients received ketamine infusion in combination with 12 TIMBER sessions (3 sessions in the first week followed by 9 sessions conducted on a weekly basis) and TIMBER-P group patients received placebo (normal saline infusion) in combination with 12 TIMBER sessions. The patients in the TIMBER-P group were switched to those in the TIMBER-K group after they experienced a sustained relapse. Outcome measures: PTSD Checklist (PCL), Clinician Administered PTSD Scale for DSM-IV (CAPS), the 17-item Hamilton Rating Scale for Depression (Ham-D-17, clinician rated), Beck Anxiety Inventory (BAI), and Montreal Cognitive Assessment (MoCA) at baseline and 8 hours after infusion were used to investigate if ketamine selectively affected trauma memories leaving the general memory intact. The mindfulness interventions in TIMBER were personalized based on subject's scores on Assessment Scale for Mindfulness Interventions which was administered at baseline, and after 5 sessions and 9 sessions (completion) of TIMBER. In this study, scores on CAPS and PCL scales were the primary outcome measures.
Results: In the acute phase trial ( first 3 months after infusion), nine out of 10 subjects showed robust response in primary outcome measures (PCL and CAPS scores for PTSD) and in the secondary outcome measures (Ham-D-17 and Beck Anxiety Inventory for depression and anxiety respectively) with a sustained response of 31.78 ± 18.29 days. The TIMBER-K group had a more sustained response (33 ± 22.98 days) compared to the TIMBER-P group (25 ± 16.8 days, P = 0.545). After switch from TIMBER-P group to TIMBER-K, patients experienced significantly prolonged response (49 vs. 25 days, P = 0.028). There were no intolerable side effects or dropouts during the 18-month follow-up period.
Conclusion: TIMBER psychotherapy augmented with low dose (R,S)-ketamine prolongs the therapeutic effects of the later and may be a valuable treatment option for PTSD.
Trial Registration: ClinicalTrials.gov identifier: NCT02766192
Comparable studies
Other randomized controlled trials on ketamine for PTSD, most cited first.
Citations in the library
Cited by 33
- Reviewing the Potential of Psychedelics for the Treatment of PTSD The International Journal of Neuropsychopharmacology March 12, 2020
- Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions Frontiers in Psychology June 10, 2022
- Psilocybin and MDMA for the treatment of trauma-related psychopathology International Review of Psychiatry April 3, 2021
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment Current Neuropharmacology January 5, 2024
- Long term structural and functional neural changes following a single infusion of Ketamine in PTSD Neuropsychopharmacology June 3, 2023
and 28 more in the library
Cites 6
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder JAMA Psychiatry April 16, 2014
- D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression Psychopharmacology July 24, 2014
and 1 more in the library